ASU Health Futures Center 331B 6161 E Mayo Blvd
Phoenix, AZ 85054
Mail code: 4501
Campus: Tempe
Long Bio
Douglas Lake is a tumor immunologist who has been at ASU since 2006. Previously, he was at the University of Arizona Cancer Center where he studied anti-tumor T cells and tumor-associated peptides as immunotherapy targets.
Currently, he is investigating an enzyme called QSOX1 that is over-expressed in multiple tumor types. Lake was the first to show that this enzyme is important in tumor cell growth, invasion and metastasis. His laboratory is developing chemical and biological inhibitors of QSOX1 with strong therapeutic potential.
His laboratory also studies Valley Fever (Coccidioidomycosis). A pressing clinical need is that Valley Fever lacks an accurate and sensitive diagnostic test while patients are acutely symptomatic. Because the current test relies on an immune respone, which is often delayed in this disease, patients can go for as long as three months without a diagnosis. As a result, many patients are inappropriately treated. Lake is developing a test that detects bits and pieces of the fungus in urine in infected patients.
To address the needs of the COVID-19 pandemic, Dr. Lake developed a specialized rapid antibody test that measures levels of protective neutralizing antibodies which prevent SARS-CoV-2 from infecting cells. Using this rapid test (10 minutes) and a finger-stick drop of blood, one can monitor levels of neutralizing antibodies after vaccination or natural infection to determine when one might require an additional vaccine dose.
In addition, Lake teaches immunology and microbiology at the undergraduate level and advance cell biology at the graduate level.
Publications
Hanavan PD, Borges CR, Katchman BA, Faigel DO, Ho TH, Ma CT, Sergienko EA, Meurice N, Petit JL, Lake DF. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cell lines. Oncotarget (2015).
43. Bhattacharya S, Chai T-C, Aryasinghe N, Ruiz Y, Lake D, Ros R. Selective trapping of single mammalian breast cancer cells by insulator-based dielectrophoresis. Anal. Bioanal Chem (2014).
Blair JE, Chang YH, Ruiz Y, Duffy S, Heinrich BE, Lake DF. Distance from construction site and risk for coccidioidomycosis, Arizona, USA. Emerging Infectious Diseases (2014).
Borges, CR and Lake DF. Oxidative Protein Folding: Nature’s knotty challenge. Antioxidants and Redox Signaling (2014).
Lake, DF and Faigel DO. The Emerging Role of QSOX1 in Cancer. Anti-oxidant and redox signaling (2014).
Editors: Bertram Katzung, Susan Masters, Anthony Trevor Chapter 56: Douglas Lake and Adrienne Briggs. Basic and Clinical Pharmacology, Chapter 56. (2014).
Antwi K, Hanavan P, Myers CE, Ruiz Y, Thompson EJ, and Lake DF. Identification of an MHC-binding Peptidome from Pancreas and Breast Cancer Cell Lines. Molecular Immunology (2009).
Antwi K, Hostetter G, Demeure MJ, Decker GA, Ruiz Y, Sielaff T, Koep L and Lake DF. Analysis of Human Plasma Peptidome Reveals Potential Biomarker for Pancreatic Cancer. Journal of Proteome Research (2009).
Redman H, Marlowe M, Hanavan P, Lake DF, Endres RO. Discovery of a novel HLA-Cw*08 allele, Cw*0817. Tissue Antigens (2009).
S Dionne, A Podany, Y Ruiz, N Ampel, J Galgiani, Douglas Lake. Spherules derived from Coccidioides posadasii promote dendritic cell maturation and activation. Infect. Immun (2006).
N Ampel, D Nelson, L Li, S Dionne, Douglas Lake, K Simmons, D Pappagianis. The mannose receptor mediates the cellular immune response in human coccidioidomycosis. Infect Immun (2005).
A Quinn, E Sercarz, J Im, Douglas Lake. Molecular Profile of the T Cell Receptors of regulatory and effector CD4+ T cells recognizing overlapping determinants on Glutamic Acid Decarboxylase (524-543). Molecular immunology (2004).
S Dionne, C Myers, M Smith, Douglas Lake. Reactivity of anti-Her-2/neu CTL to Her-2/neu modified peptides. Cancer Immunol. Immunother (2004).
S Dionne, Douglas Lake, W Grimes, M Smith. Identification of HLA-Cw6.02 and -Cw7.01 allele-specific binding motifs by screening synthetic peptide libraries. Immunogenetics (2004).
S Klotz, N Gaur, Douglas Lake, V Chan, J Rauceo, P Lipke. Degenerate Peptide Recognition by Candida albicans Adhesins Als5p and Als1p. Infection and Immunity (2004).
S Klotz, N Gaur, J Rauceo, Douglas Lake, Y Park, K Hahm, P Lipke. Inhibition of adherence and killing of Candida albicans with a 23-Mer peptide (Fn/23) with dual antifungal properties. Antimicrob Agents Chemother (2004).
X Tang, D Yocum, D Dejonghe, K Nordensson, Douglas Lake, J Richards. Increased activation-induced cell death in peripheral lymphocytes of rheumatoid arthritis patients: the mechanism of action. Immunology (2004).
S Dionne, M Smith, F Marincola, Douglas Lake. Functional Characterization of CTL Against gp100 Altered Peptide Ligands. Cancer Immunol and Immunother (2003).
J Richards, N Ampel, Douglas Lake. Reversal of coccidioidal anergy by dendritic cells from patients with disseminated coccidioidomycosis. J. Immunol (2002).
J Richards, N Ampel, J Galgiani, Douglas Lake. Coccidioides immitis lysate induces dendritic cell maturation and activates naïve T cells. Journal of Infectious Diseases (2001).
S Dionne, M Smith, Douglas Lake. CTL stimulation elicited by bead-bound antigenic peptides. Cellular Immunology (2001).
Douglas Lake, W Huynh, E Hersh. Natural and Induced Human Antibody Response to Cancer. Cancer Investigation (2000).
Research Activity
Lake,Douglas Fletcher. High Throughput Screening to Discover Chemical Inhibitors of Quiescin Sulfhydryl Oxidase 1. MAYO CLINIC SCOTTSDALE(7/20/2016 - 6/30/2019).
Lake,Douglas Fletcher. MCA MEGA Acute Valley Fever and the Diagnostic Desert: Meeting the Need for a Diagnostic Test. MAYO CLINIC SCOTTSDALE(5/8/2016 - 8/12/2016).
Lake,Douglas Fletcher. Discovery of Regulatory Molecules on T Regulatory cells. (2/4/2016 - 2/3/2017).
Lake,Douglas Fletcher. QSOX1 Inhibitors Development into a Clinically Applicable Anticancer Drug by Generating RCC Mouse Xenograft Models. MAYO CLINIC SCOTTSDALE(8/2/2015 - 9/15/2016).
Lake,Douglas Fletcher. QS0X1 Function Evaluation in Kidney Cancer. MAYO CLINIC SCOTTSDALE(5/11/2015 - 3/31/2016).
Lake,Douglas Fletcher. Discovery of Regulatory Molecules on T Regulatory cells. (1/31/2014 - 1/30/2016).
Kusumi,Kenro*, Lake,Douglas Fletcher. Connecting the proteome and transcriptome during regeneration. HHS-NIH-NIAMS(9/1/2013 - 8/31/2016).
Lake,Douglas Fletcher. Plasma-based Detection of Valley Fever. ASU-Mayo Seed Grant(2/1/2012 - 6/30/2012).
Lake,Douglas Fletcher. Animal study to Determine if QSOX1 is an Anti-neoplastic Therapeutic Target. ASU-Mayo Seed Grant(1/1/2012 - 5/1/2013).
Lake,Douglas Fletcher. A Survey of Coccidiomycosis Among Employees at Mayo Clinic Arizona During a Major Construction Project (The Big Dig). MAYO CLINIC SCOTTSDALE(12/9/2011 - 12/8/2013).
Lake,Douglas Fletcher. Plasma-Based Detection of Valley Fever. MAYO CLINIC SCOTTSDALE(1/1/2010 - 12/31/2010).
Lake,Douglas Fletcher. Working Backwards from the Proteome. HHS-NIH-NIGMS(9/4/2009 - 8/31/2014).
Lake,Douglas Fletcher. Evaluation of the Plasma Peptidome and Its Correlation to the Tumor Proteome. TGen(3/1/2009 - 8/31/2011).
Lake,Douglas Fletcher. Plasma-based Biomarkers for Early Detection of Pancreatic Cancer. MAYO CLINIC SCOTTSDALE(1/1/2009 - 12/31/2009).
Lake,Douglas Fletcher. Test human sera and peripheral blood lymphocytes for reactivity to AZX100. ORTHOLOGIC(2/14/2007 - 5/14/2007).
Joshi,Lokesh*, Lake,Douglas Fletcher, Svarovsky,Sergei. Discovery and Validation of Novel Glycan-Binding Peptides specific for Cancer-Glycobiomarkers for the Detection of Pancreatic and Breast Cancers. MAYO CLINIC SCOTTSDALE(11/1/2006 - 10/31/2007).
Lake,Douglas Fletcher. Engineered and Proteolytic Antibodies Specific for HIV-1gp 120. HHS-NIH-NIAID(1/7/2006 - 8/31/2009).
Lake,Douglas Fletcher. Custom-Designing Peptides for Cancer Immunotherapy. NCI(1/7/2006 - 2/28/2007).
Lake,Douglas Fletcher. Dendritic Cells and Immunity of Valley Fever. ABRC(7/1/2005 - 10/31/2007).
Yasmynn Chowdhury1, Setu Kaushal1, Tom Grys2, Janis A. Blair3, Yvette Ruiz1, D. Mitchell Magee4, Thomas V. Colby5 and Douglas F. Lake. A Survey of Lectin Reactivity to Coccidioides in Infected Human Lung. 58th Annual Coccidioidomycosis Study Group (Apr 2015).
Lake D, Grys T, Kaushal S, Koliopolis A, Blair JE. Identification of Lectin-binding Coccidioidal Glycoproteins. 59th Annual Coccidioidomycosis Study Group (Apr 2015).
Douglas Lake, Douglas Faigel, Benjamin Katchman, Kwasi Antwi, Daniel D. Von Hoff, Michael J. Demeure. QSOX1 promotes pancreatic tumor cell invasion. Digestive Diseases Week (May 2013).
Douglas F. Lake, Benjamin A. Katchman, Kwasi Antwi, Michael J. Demeure, and Douglas O. Faigel. QSOX1 as an Anti-neoplastic Target with a Plasma-based Peptide Biomarker. Tucson Symposium (Mar 2013).
Lake D.F.*, Blair J.E., Pitta T., Antwi K., Stolper R., Duffy S., Hanavan P. Identification of Peptides in plasma from Coccidioides by Mass Spectrometry. 55th Annual Coccidioidomycosis Study Group (Apr 2011).
Douglas Lake. Connecting biomarkers in plasma to tumors. ADAPT 2010, Track 3 biomarkers (Sep 2010).
Douglas Lake. Discovery of Novel Tumor-Derived Antigenic Peptides. University of Arizona College of Medicine (Jun 2009).
Douglas Lake, Kwasi Antwi1 Phillip Stafford, HoJoon Lee, Paul Hanavan, Yvette Ruiz, Stephen Albert Johnston, Randall Nelson, Michael Demeure and Daniel D. Von Hoff3. Detection of Tumor-Derived Peptides in Pancreas Cancer Patient Plasma. American Association for Cancer Research Annual Meeting April 12-16, 2008 (Apr 2009).
Douglas Lake. Proteomics for Cancer Biomarker Discovery. Biozona (Apr 2009).
Service
NIH Study section: Transplantation Tolerance and Tumor Immunity, Reviewer (2006 - Present)
